Cargando…
Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207
Gemcitabine serves as a first‐line chemotherapy agent for advanced pancreatic cancer (PC). However, the molecular basis by which gemcitabine exerts its effects is not well‐established, and the targeted genetic pathways remain unclear. Pvt1 oncogene (non‐protein coding) (PVT1) has been reported to be...
Autores principales: | You, Lei, Wang, Huanyu, Yang, Gang, Zhao, Fangyu, Zhang, Jingcheng, Liu, Ziwen, Zhang, Taiping, Liang, Zhiyong, Liu, Changzheng, Zhao, Yupei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275279/ https://www.ncbi.nlm.nih.gov/pubmed/30341811 http://dx.doi.org/10.1002/1878-0261.12393 |
Ejemplares similares
-
Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
por: Luo, Wenhao, et al.
Publicado: (2019) -
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Xiong, Guangbing, et al.
Publicado: (2018) -
PVT1‐derived miR‐1207‐5p promotes breast cancer cell growth by targeting STAT6
por: Yan, Chen, et al.
Publicado: (2017) -
Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Xiong, Guangbing, et al.
Publicado: (2021) -
Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer
por: Xiong, Guangbing, et al.
Publicado: (2019)